Research Project
Grant-in-Aid for Scientific Research (B)
Severe rhabdomyolysis, which occurs in disasters and accidents, often complicates with acute kidney injury (AKI), leading to a fatal case of multiple organ failure. Thus, the development of drugs that improve the prognosis is eagerly desired. “Carbon monoxide (CO)” from renal heme oxygenase (HO)-1, which is activated by rhabdomyolysis-induced AKI, plays an important role as a stress response defense mechanism in kidney. In the present study, to develop a new therapeutic agent for rhabdomyolysis-induced AKI, we created a CO-releasing nano-formulation, that can be used in various situations such as disasters, using hemoglobin as a CO-carrier. We further loaded a renal-oriented peptide to the formulation and developed a "renal CO delivery system". Finally, we demonstrated its preventive and therapeutic effect using rhabdomyolysis model animals.
“クラッシュ症候群”は外傷性横紋筋融解症の一つである。阪神大震災や福知山列車事故など、本邦のように災害や事故が多発する状況下では、横紋筋融解症AKIに対する治療法の開発は重要かつ急務であるが、医療機関だけでなく、災害現場でも使用可能で予後を改善する有効な治療法は存在せず、現行では輸液や頻回な血液透析等の対処療法に留まっている。申請者は、熊本地震に被災した際に、この点を強く実感した。本邦のような災害・事故多発国において、横紋筋融解症の予後改善を企図とした薬剤を開発する意義は高い。
All 2021 2020 2019 2018
All Journal Article (37 results) (of which Int'l Joint Research: 6 results, Peer Reviewed: 37 results, Open Access: 35 results) Presentation (7 results) (of which Int'l Joint Research: 3 results, Invited: 1 results) Book (1 results) Patent(Industrial Property Rights) (2 results) (of which Overseas: 1 results)
Biological and Pharmaceutical Bulletin
Volume: 44 Issue: 3 Pages: 437-441
10.1248/bpb.b20-00929
130007993459
Diabetes Care
Volume: 26 Issue: 6 Pages: e115-e117
10.2337/dc20-3003
Sci Rep.
Volume: 12;11(1) Issue: 1 Pages: 7953-7953
10.1038/s41598-021-87217-8
ACS Applied Bio Materials
Volume: 4,5 Pages: 4302-4309
10.1016/j.lfs.2020.118991
Life Sci
Volume: 1;268 Issue: 1 Pages: 118991-118991
10.1111/1744-9987.13500
Volume: 43 Issue: 10 Pages: 1583-1590
10.1248/bpb.b20-00472
130007920876
Chemical and Pharmaceutical Bulletin
Volume: 68 Issue: 7 Pages: 583-588
10.1248/cpb.c20-00026
130007867325
YAKUGAKU ZASSHI
Volume: 140 Issue: 2 Pages: 141-146
10.1248/yakushi.19-00187-1
130007793385
Volume: 43 Issue: 1 Pages: 93-101
10.1248/bpb.b19-00599
130007779193
International Journal of Biological Macromolecules
Volume: 164 Pages: 659-666
10.1016/j.ijbiomac.2020.07.184
Sci Rep
Volume: 26;10(1): Issue: 1 Pages: 20635-20635
10.1038/s41598-020-75025-5
Antioxidants
Volume: 9 Issue: 10 Pages: 965-965
10.3390/antiox9100965
Journal of Pharmaceutical Sciences
Volume: 109 Issue: 9 Pages: 2919-2924
10.1016/j.xphs.2020.06.011
Toxins (Basel)
Volume: 5;12(8): Issue: 8 Pages: 502-502
10.3390/toxins12080502
J Control Release
Volume: 10;324: Pages: 522-531
10.1016/j.jconrel.2020.05.036
Scientific Reports
Volume: 10 Issue: 1 Pages: 11424-11424
10.1038/s41598-020-68337-z
Kidney360
Volume: 1 Issue: 8 Pages: 781-796
10.34067/kid.0000772019
Clin Biochem
Volume: 81 Pages: 20-26
10.1016/j.clinbiochem.2020.04.010
PLoS One
Volume: 15 Issue: 6 Pages: 20-26
10.1371/journal.pone.0233925
Volume: 9 Issue: 5 Pages: 387-387
10.3390/antiox9050387
Volume: ー Issue: 5 Pages: 343-353
10.34067/kid.0000782019
Volume: -
120007146111
J Pharmacol Exp Ther
Volume: 372(3) Issue: 3 Pages: 355-365
10.1124/jpet.119.262485
Volume: 42 Issue: 5 Pages: 786-791
10.1248/bpb.b18-00976
130007641447
FASEB BioAdvances
Volume: 1 Issue: 3 Pages: 137-150
10.1096/fba.1018
120007153321
IUBMB Life
Volume: 72 Issue: 4 Pages: 641-651
10.1002/iub.2203
Mol Pharm.
Volume: 16(10) Issue: 10 Pages: 4131-4138
10.1021/acs.molpharmaceut.9b00435
J Pharm Sci.
Volume: 108(11) Issue: 11 Pages: 3592-3598
10.1016/j.xphs.2019.07.002
Journal of Controlled Release
Volume: 304 Pages: 156-163
10.1016/j.jconrel.2019.05.015
Molecules
Volume: 24 Issue: 9 Pages: 1689-1689
10.3390/molecules24091689
120006995454
Volume: 26 Issue: 1 Pages: 17329-17329
10.1038/s41598-018-35339-x
Drug Deliv
Volume: 25 Issue: 1 Pages: 1266-1274
10.1080/10717544.2018.1477860
J Pharm Sci
Volume: 107 Issue: 3 Pages: 848-855
10.1016/j.xphs.2017.10.023